Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
- PMID: 32861807
- DOI: 10.1016/j.annonc.2020.08.2099
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Erratum in
-
Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490].Ann Oncol. 2023 Jul;34(7):631. doi: 10.1016/j.annonc.2022.12.006. Epub 2022 Dec 21. Ann Oncol. 2023. PMID: 36564283 No abstract available.
Keywords: Clinical Practice Guidelines; adrenal cancer; diagnosis; follow-up; treatment.
Conflict of interest statement
Disclosure MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA, CdlF, GE, FP and Rdk have declared no potential conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical